These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 37909987)

  • 41. Cell-Free DNA Next-Generation Sequencing Prediction of Response and Resistance to Third-Generation EGFR Inhibitor.
    Helman E; Nguyen M; Karlovich CA; Despain D; Choquette AK; Spira AI; Yu HA; Camidge DR; Harding TC; Lanman RB; Simmons AD
    Clin Lung Cancer; 2018 Nov; 19(6):518-530.e7. PubMed ID: 30279111
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Role of Circulating Tumor DNA Profiling in Patients with Non-Small Cell Lung Cancer Treated with EGFR Inhibitor.
    Ku BM; Kim YJ; Park D; Lee SH; Ahn JS; Park K; Ahn MJ; Sun JM
    Oncology; 2022; 100(4):228-237. PubMed ID: 35196661
    [TBL] [Abstract][Full Text] [Related]  

  • 43. EGFR-Mutated Lung Cancers Resistant to Osimertinib through EGFR C797S Respond to First-Generation Reversible EGFR Inhibitors but Eventually Acquire EGFR T790M/C797S in Preclinical Models and Clinical Samples.
    Rangachari D; To C; Shpilsky JE; VanderLaan PA; Kobayashi SS; Mushajiang M; Lau CJ; Paweletz CP; Oxnard GR; Jänne PA; Costa DB
    J Thorac Oncol; 2019 Nov; 14(11):1995-2002. PubMed ID: 31377341
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Impact of coexisting gene mutations in EGFR-mutated non-small cell lung cancer before treatment on EGFR T790M mutation status after EGFR-TKIs.
    Takeda M; Sakai K; Hayashi H; Tanaka K; Haratani K; Takahama T; Kato R; Yonesaka K; Nishio K; Nakagawa K
    Lung Cancer; 2020 Jan; 139():28-34. PubMed ID: 31710890
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Efficacy of different platforms in detecting EGFR mutations using cerebrospinal fluid cell-free DNA from non-small-cell lung cancer patients with leptomeningeal metastases.
    Chiang CL; Ho HL; Yeh YC; Lee CC; Huang HC; Shen CI; Luo YH; Chen YM; Chiu CH; Chou TY
    Thorac Cancer; 2023 May; 14(14):1251-1259. PubMed ID: 36977550
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prospective Observational Study of Treatment Resistance-related Gene Screening Using Plasma Circulating Tumor DNA in Third-generation EGFR-TKI Osimertinib Therapy (Elucidator).
    Tamiya A; Isa SI; Taniguchi Y; Nakagawa H; Atagi S; Ando M; Koh Y
    Clin Lung Cancer; 2021 May; 22(3):e336-e341. PubMed ID: 32641247
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effective osimertinib treatment in a patient with discordant T790 M mutation detection between liquid biopsy and tissue biopsy.
    Mambetsariev I; Vora L; Yu KW; Salgia R
    BMC Cancer; 2018 Mar; 18(1):314. PubMed ID: 29562902
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study.
    Lin CC; Shih JY; Yu CJ; Ho CC; Liao WY; Lee JH; Tsai TH; Su KY; Hsieh MS; Chang YL; Bai YY; Huang DD; Thress KS; Yang JC
    Lancet Respir Med; 2018 Feb; 6(2):107-116. PubMed ID: 29249325
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prevalence of T790M mutation among TKI-therapy resistant Lebanese lung cancer patients based on liquid biopsy analysis: a first report from a major tertiary care center.
    Assi H; Tfayli A; Assaf N; Daya SA; Bidikian AH; Kawsarani D; Fermanian P; Zaatari G; Mahfouz R
    Mol Biol Rep; 2019 Aug; 46(4):3671-3676. PubMed ID: 31147859
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Osimertinib, a third-generation EGFR tyrosine kinase inhibitor: A retrospective multicenter study of its real-world efficacy and safety in advanced/recurrent non-small cell lung carcinoma.
    Kishikawa T; Kasai T; Okada M; Nakachi I; Soda S; Arai R; Takigami A; Sata M
    Thorac Cancer; 2020 Apr; 11(4):935-942. PubMed ID: 32129931
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Barcode sequencing identifies resistant mechanisms to epidermal growth factor receptor inhibitors in circulating tumor DNA of lung cancer patients.
    Kitazono S; Sakai K; Yanagitani N; Ariyasu R; Yoshizawa T; Dotsu Y; Koyama J; Saiki M; Sonoda T; Nishikawa S; Uchibori K; Horiike A; Nishio K; Nishio M
    Cancer Sci; 2019 Oct; 110(10):3350-3357. PubMed ID: 31361375
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Mutational Profiling of Non-Small-Cell Lung Cancer Resistant to Osimertinib Using Next-Generation Sequencing in Chinese Patients.
    Nie K; Jiang H; Zhang C; Geng C; Xu X; Zhang L; Zhang H; Zhang Z; Lan K; Ji Y
    Biomed Res Int; 2018; 2018():9010353. PubMed ID: 29713646
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Next-generation sequencing of tissue and circulating tumor DNA: Resistance mechanisms to EGFR targeted therapy in a cohort of patients with advanced non-small cell lung cancer.
    Zhang Y; Xiong L; Xie F; Zheng X; Li Y; Zhu L; Sun J
    Cancer Med; 2021 Jul; 10(14):4697-4709. PubMed ID: 34173341
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Sputum cell-free DNA: Valued surrogate sample for the detection of EGFR exon 20 p.T790M mutation in patients with advanced lung adenocarcinoma and acquired resistance to EGFR-TKIs.
    Wang Z; Li X; Zhang L; Xu Y; Wang M; Liang L; Jiao P; Li Y; He S; Du J; He L; Tang M; Sun M; Yang L; Di J; Zhu G; Li L; Liu D
    Cancer Med; 2021 May; 10(10):3323-3331. PubMed ID: 33932095
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Mechanisms of primary resistance to EGFR targeted therapy in advanced lung adenocarcinomas.
    Jin Y; Shi X; Zhao J; He Q; Chen M; Yan J; Ou Q; Wu X; Shao YW; Yu X
    Lung Cancer; 2018 Oct; 124():110-116. PubMed ID: 30268447
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Profiling of circulating tumor DNA in plasma of non-small cell lung cancer patients, monitoring of epidermal growth factor receptor p.T790M mutated allelic fraction using beads, emulsion, amplification, and magnetics companion assay and evaluation in future application in mimicking circulating tumor cells.
    Garcia J; Wozny AS; Geiguer F; Delherme A; Barthelemy D; Merle P; Tissot C; Jones FS; Johnson C; Xing X; Xu Z; Edelstein DL; Brevet M; Souquet PJ; Rodriguez-Lafrasse C; Payen L; Couraud S
    Cancer Med; 2019 Jul; 8(8):3685-3697. PubMed ID: 31112372
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Plasma ctDNA monitoring during epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor treatment in patients with EGFR-mutant non-small cell lung cancer (JP-CLEAR trial).
    Usui K; Yokoyama T; Naka G; Ishida H; Kishi K; Uemura K; Ohashi Y; Kunitoh H
    Jpn J Clin Oncol; 2019 Jun; 49(6):554-558. PubMed ID: 30809659
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clinical characteristics of T790M-positive lung adenocarcinoma after resistance to epidermal growth factor receptor-tyrosine kinase inhibitors with an emphasis on brain metastasis and survival.
    Joo JW; Hong MH; Shim HS
    Lung Cancer; 2018 Jul; 121():12-17. PubMed ID: 29858020
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Be-TeaM: An Italian real-world observational study on second-line therapy for EGFR-mutated NSCLC patients.
    Reale ML; Chiari R; Tiseo M; Vitiello F; Barbieri F; Cortinovis D; Ceresoli GL; Finocchiaro G; Romano GD; Piovano PL; Del Conte A; Borra G; Verderame F; Scotti V; Nonnis D; Galetta D; Sergi C; Migliorino MR; Tonini G; Cecere F; Berardi R; Pino MS; Martelli O; Gelibter A; Carta A; Vattemi E; Pagano M; Zullo A; Ferrari S; Rossi A; Novello S
    Lung Cancer; 2020 Feb; 140():71-79. PubMed ID: 31884129
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Application of liquid biopsy-based targeted capture sequencing analysis to improve the precision treatment of non-small cell lung cancer by tyrosine kinase inhibitors.
    Zhang L; Coffin J; Formenti K; Chu Q; Izevbaye I
    BMJ Open Respir Res; 2022 Jan; 9(1):. PubMed ID: 35091437
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.